Clinical Criteria updates for specialty pharmacy are available 

Effective for dates of service on and after December 1, 2023, the following Clinical Criteria were developed and might result in services that were previously covered but may now be found to be not medically necessary.

CC-0228	Leqembi (lecanemab)
CC-0241	Elfabrio (pegunigalsidase alfa-iwxj)
CC-0243	Vyjuvek (beremagene geperpavec)

Access the Clinical Criteria document information.

Anthem Blue Cross and Blue Shield (Anthem) prior authorization clinical review of nononcology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of oncology will be managed by Carelon Medical Benefits Management, Inc.,* a separate company.